Predictive Oncology (POAI) 10-Q 10 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 06, 2015
Document Information [Line Items]
Entity Registrant Name	Skyline Medical Inc.
Entity Central Index Key	1,446,159
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	SKLN
Entity Common Stock, Shares Outstanding		3,312,863
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,015

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - Equity Component [Domain] - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash	$ 44,103	$ 16,384
Accounts Receivable	15,855	57,549
Inventories	257,668	367,367
Prepaid Expense and other assets	202,591	190,015
Total Current Assets	520,217	631,315
Fixed Assets, net	147,243	196,479
Intangibles, net	77,995	73,183
Total Assets	745,455	900,977
Current Liabilities:
Accounts Payable	2,474,186	2,194,518
Accrued Expenses	3,474,043	3,066,379
Short-term notes payable net of discounts of $0 and $194,097 (See Note 4)	933,074	937,424
Deferred Revenue	8,375	5,000
Total Current Liabilities	$ 6,889,678	6,203,321
Accrued Expenses		213,883
Total Liabilities	$ 6,889,678	$ 6,417,204
Commitments and Contingencies
Stockholders' Deficit:
Series A Convertible Preferred Stock, $.01 par value, $100 Stated Value, 20,000,000 authorized, 20,550 outstanding	$ 206	$ 206
Common Stock, $.01 par value, 100,000,000 authorized, 3,312,863 and 3,092,766 outstanding	33,128	30,927
Additional paid-in capital	30,935,472	30,093,745
Accumulated Deficit	(37,113,029)	(35,641,105)
Total Stockholders' Deficit	(6,144,223)	(5,516,227)
Total Liabilities and Stockholders' Deficit	$ 745,455	$ 900,977

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - Equity Component [Domain] - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Discount on short term note payable (in dollars)	$ 0	$ 194,097
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, stated value (in dollars per share)	$ 100	$ 100
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares outstanding	20,550	20,550
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares outstanding	3,312,863	3,092,766

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
CONDENSED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 234,012	$ 318,293	$ 385,286	$ 388,513
Cost of goods sold	83,566	98,365	179,534	129,448
Gross Margin	150,446	219,928	205,752	259,065
General and administrative expense	856,219	1,330,222	728,424	2,509,504
Operations expense	151,313	291,584	172,630	556,859
Sales and marketing expense	139,026	319,303	372,983	524,223
Interest expense	$ 189,215	$ 14,773	$ 342,837	32,897
Gain on valuation of equity-linked financial instruments				(11,469)
Total expense	$ 1,335,773	$ 1,955,882	$ 1,616,874	3,612,014
Net loss available to common shareholders	$ (1,185,327)	$ (1,735,954)	$ (1,411,122)	$ (3,352,949)
Loss per common share basic and diluted (in dollars per share)	$ (0.36)	$ (0.58)	$ (0.44)	$ (1.13)
Weighted average shares used in computation, basic and diluted (in shares)	3,263,356	2,968,279	3,182,706	2,958,965

STATEMENT OF STOCKHOLDERS' DEFI

STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Note convertible at $6.68 per share [Member]	Note convertible at $6.68 per share [Member]	Note convertible at $5.85 per share [Member]	Note convertible at $5.03 per share [Member]	Note convertible at $5.14 per share [Member]	Note convertible at $5.00 per share [Member]	Note convertible at $5.26 per share [Member]	Note convertible at $5.26 per share [Member]	Note convertible at $5.95 per share [Member]	Note convertible at $5.05 per share [Member]	Note convertible at $2.90 per share [Member]	Note convertible at $2.96 per share [Member]	Note convertible at $2.91 per share [Member]	Note convertible at $2.77 per share [Member]	Note convertible at $2.25 per share [Member]	Note convertible at $2.00 per share [Member]	Note convertible at $2.27283 per share [Member]	Note convertible at $2.0179 per share [Member]	Note convertible at $2.00 per share [Member]	Note convertible at $1.92417 per share [Member]	Note convertible at $1.8578 per share [Member]	Shares issued at $20.63 per share [Member]	Shares issued at $18.75 per share [Member]	Shares issued at $19.50 per share [Member]	Shares issued at $11.25 per share [Member]	Shares issued at $18.75 per share [Member]	Shares issued at $19.50 per share [Member]	Shares issued at $19.50 per share [Member]	Shares issued at $19.50 per share [Member]	Shares issued at $9.75 per share [Member]	Shares issued at $9.75 per share [Member]	Shares issued at $9.75 per share [Member]	Option exercisable at $1.25 per share [Member]	Option exercisable at $5.25 per share [Member]	Option exercisable at $5.25 per share [Member]	Warrant exercisable at $15.00 per share [Member]	Warrant exercisable at $12.75 per share [Member]	Warrant exercisable at $.75 per share [Member]	Warrant exercisable at $13.50 per share [Member]	Warrant exercisable at $7.50 per share [Member]	Warrant exercisable at $5.63 per share [Member]	Warrant exercisable at $12.75 per share [Member]	Warrant exercisable at $11.25 per share [Member]	Warrant exercisable at $13.50 per share [Member]	Warrant exercisable at $9.75 per share [Member]	Warrant exercisable at $5.63 per share [Member]	Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]Note convertible at $6.68 per share [Member]	Common Stock [Member]Note convertible at $6.68 per share [Member]	Common Stock [Member]Note convertible at $5.85 per share [Member]	Common Stock [Member]Note convertible at $5.03 per share [Member]	Common Stock [Member]Note convertible at $5.14 per share [Member]	Common Stock [Member]Note convertible at $5.00 per share [Member]	Common Stock [Member]Note convertible at $5.26 per share [Member]	Common Stock [Member]Note convertible at $5.26 per share [Member]	Common Stock [Member]Note convertible at $5.95 per share [Member]	Common Stock [Member]Note convertible at $5.05 per share [Member]	Common Stock [Member]Note convertible at $2.90 per share [Member]	Common Stock [Member]Note convertible at $2.96 per share [Member]	Common Stock [Member]Note convertible at $2.91 per share [Member]	Common Stock [Member]Note convertible at $2.77 per share [Member]	Common Stock [Member]Note convertible at $2.25 per share [Member]	Common Stock [Member]Note convertible at $2.00 per share [Member]	Common Stock [Member]Note convertible at $2.27283 per share [Member]	Common Stock [Member]Note convertible at $2.0179 per share [Member]	Common Stock [Member]Note convertible at $2.00 per share [Member]	Common Stock [Member]Note convertible at $1.92417 per share [Member]	Common Stock [Member]Note convertible at $1.8578 per share [Member]	Common Stock [Member]Shares issued at $20.63 per share [Member]	Common Stock [Member]Shares issued at $18.75 per share [Member]	Common Stock [Member]Shares issued at $19.50 per share [Member]	Common Stock [Member]Shares issued at $11.25 per share [Member]	Common Stock [Member]Shares issued at $18.75 per share [Member]	Common Stock [Member]Shares issued at $19.50 per share [Member]	Common Stock [Member]Shares issued at $19.50 per share [Member]	Common Stock [Member]Shares issued at $19.50 per share [Member]	Common Stock [Member]Shares issued at $9.75 per share [Member]	Common Stock [Member]Shares issued at $9.75 per share [Member]	Common Stock [Member]Shares issued at $9.75 per share [Member]	Common Stock [Member]Option exercisable at $1.25 per share [Member]	Common Stock [Member]Option exercisable at $5.25 per share [Member]	Common Stock [Member]Option exercisable at $5.25 per share [Member]	Common Stock [Member]Warrant exercisable at $15.00 per share [Member]	Common Stock [Member]Warrant exercisable at $12.75 per share [Member]	Common Stock [Member]Warrant exercisable at $.75 per share [Member]	Common Stock [Member]Warrant exercisable at $13.50 per share [Member]	Common Stock [Member]Warrant exercisable at $7.50 per share [Member]	Common Stock [Member]Warrant exercisable at $5.63 per share [Member]	Common Stock [Member]Warrant exercisable at $12.75 per share [Member]	Common Stock [Member]Warrant exercisable at $11.25 per share [Member]	Common Stock [Member]Warrant exercisable at $13.50 per share [Member]	Common Stock [Member]Warrant exercisable at $9.75 per share [Member]	Common Stock [Member]Warrant exercisable at $5.63 per share [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Note convertible at $6.68 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $6.68 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $5.85 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $5.03 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $5.14 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $5.00 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $5.26 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $5.26 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $5.95 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $5.05 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $2.90 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $2.96 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $2.91 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $2.77 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $2.25 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $2.00 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $2.27283 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $2.0179 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $2.00 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $1.92417 per share [Member]	Additional Paid-in Capital [Member]Note convertible at $1.8578 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $20.63 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $18.75 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $19.50 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $11.25 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $18.75 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $19.50 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $19.50 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $19.50 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $9.75 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $9.75 per share [Member]	Additional Paid-in Capital [Member]Shares issued at $9.75 per share [Member]	Additional Paid-in Capital [Member]Option exercisable at $1.25 per share [Member]	Additional Paid-in Capital [Member]Option exercisable at $5.25 per share [Member]	Additional Paid-in Capital [Member]Option exercisable at $5.25 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $15.00 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $12.75 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $.75 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $13.50 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $7.50 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $5.63 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $12.75 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $11.25 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $13.50 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $9.75 per share [Member]	Additional Paid-in Capital [Member]Warrant exercisable at $5.63 per share [Member]	Deficit [Member]	Deficit [Member]Shares issued at $19.50 per share [Member]	Deficit [Member]Shares issued at $19.50 per share [Member]	Deficit [Member]Shares issued at $19.50 per share [Member]	Deficit [Member]Shares issued at $19.50 per share [Member]	Deficit [Member]Shares issued at $9.75 per share [Member]	Deficit [Member]Shares issued at $9.75 per share [Member]	Deficit [Member]Shares issued at $9.75 per share [Member]
Balance at Dec. 31, 2013	$ (3,218,454)																																																$ 29,325																																															$ 25,449,636																																															$ (28,697,415)
Balance (in shares) at Dec. 31, 2013																																																	2,932,501
Shares issued for warrant exercise																																					$ 1,296	$ 2,493	$ 1,630	$ 36,000	$ 3,605	$ 2,333	$ 224		$ 2,794	$ 1,058	$ 62,500																																						$ 17	$ 33	$ 22	$ 27	$ 48	$ 31	$ 3		$ 37	$ 14	$ 111																																					$ 1,279	$ 2,460	$ 1,608	$ 35,973	$ 3,557	$ 2,302	$ 221		$ 2,757	$ 1,044	$ 62,389
Shares issued for warrant exercise, shares																																																																																					1,728	3,323	2,174	2,667	4,807	3,112	299		3,725	1,410	11,111
Shares issued for option exercise																																		$ 5,430	$ 1,400	$ 1,750																																														$ 43	$ 3	$ 3																																													$ 5,387	$ 1,397	$ 1,747
Shares issued for option exercise, shares																																																																																		4,336	267	333
Shares issued as Investor Relations compensation																							$ 41,250	$ 25,000		$ 24,000	$ 25,000																																												$ 20	$ 13		$ 21	$ 13																																											$ 41,230	$ 24,987		$ 23,979	$ 24,987
Shares issued as Investor Relations compensation, shares																																																																							2,000	1,333		2,133	1,333
Value of reduction in escrow account per settlement agreement.	(3,333)																																																$ (44)																																															(3,289)
Reduction in escrow account per settlement agreement, shares																																																	(4,444)
Shares issued to 16 shareholders of Series A Convertible Preferred Stock																														$ (1)														$ 52,500																													$ 10			$ 16	$ 16	$ 16														$ 78																												$ 18,909			$ 30,384	$ 30,385	$ 30,385														$ 52,422					$ (18,919)	$ (30,400)	$ (30,401)	$ (30,402)
Shares issued to 16 shareholders of Series A Convertible Preferred Stock, shares																																																																									972			1,561	1,561	1,561														7,778
Vesting Expense	705,434																																																																																															705,434
Options issued as part of employee bonus	694,500																																																																																															694,500
Issuance of Preferred stock	2,055,001																																															$ 206																																																2,054,795
Value of equity instruments issued with debt	$ 313,175																																																																																															313,175
Shares issued for a note conversion		$ 20,000	$ 20,000	$ 20,000	$ 20,000	$ 20,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 280,616																																							$ 30	$ 30	$ 34	$ 38	$ 39	$ 40	$ 38	$ 57	$ 50	$ 556																																						$ 19,970	$ 19,970	$ 19,966	$ 19,962	$ 19,961	$ 19,960	$ 19,962	$ 29,943	$ 29,950	$ 280,060
Shares issued for a note conversion, shares	1,559																																																	3,018	3,019	3,435	3,894	3,894	3,997	3,804	5,706	5,044	55,568
Shares issued into an escrow account per settlement agreement	$ 137																																																$ 137
Shares issued into an escrow account per settlement agreement, shares																																																	13,700
Shares adjusted for rounding per reverse stock split	2																																																$ 1																																															$ 1
Shares adjusted for rounding per reverse stock split, shares																																																	106
Net loss	(6,833,568)																																																																																																																																														$ (6,833,568)
Balance at Dec. 31, 2014	(5,516,227)																																															206	$ 30,927																																															$ 30,093,745																																															(35,641,105)
Balance (in shares) at Dec. 31, 2014																																																	3,092,766
Value of reduction in escrow account per settlement agreement.	(3,333)																																																$ (44)																																															(3,289)
Reduction in escrow account per settlement agreement, shares																																																	(4,444)
Shares issued to 16 shareholders of Series A Convertible Preferred Stock																																$ (1)	$ 1																																														$ 31	$ 31	$ 31																																													$ (31)	$ 30,369	$ 30,371																					$ (30,401)	$ (30,401)
Shares issued to 16 shareholders of Series A Convertible Preferred Stock, shares																																																																															3,122	3,121	3,121
Vesting Expense	302,981																																																																																															$ 302,981
Issuance of Preferred stock	2,055,000
Shares issued for a note conversion												$ 10,000	$ 20,000	$ 30,000	$ 33,478	$ 35,000	$ 40,000	$ 200,000	$ 30,000	$ 30,000	$ 25,000	$ 30,000																																						$ 34	$ 68	$ 103	$ 120	$ 156	$ 200	$ 880	$ 149	$ 150	$ 130	$ 162																																					$ 9,966	$ 19,932	$ 29,897	$ 33,358	$ 34,844	$ 39,800	$ 199,120	$ 29,851	$ 29,850	$ 24,870	$ 29,838
Shares issued for a note conversion, shares																																																												3,447	6,762	10,313	12,098	15,552	20,000	87,997	14,867	15,000	12,993	16,148
Net loss	(1,411,122)																																																																																																																																														(1,411,122)
Balance at Jun. 30, 2015	$ (6,144,223)																																															$ 206	$ 33,128																																															$ 30,935,472																																															$ (37,113,029)
Balance (in shares) at Jun. 30, 2015																																																	3,312,863

STATEMENT OF STOCKHOLDERS' DEF6

STATEMENT OF STOCKHOLDERS' DEFICIT (Parenthetical)	6 Months Ended	12 Months Ended
	Jun. 30, 2015item$ / shares	Dec. 31, 2014item$ / shares
Note convertible at $6.68 per share [Member]
Shares issued for a note conversion, conversion price		$ 6.68
Note convertible at $6.68 per share [Member]
Shares issued for a note conversion, conversion price		6.68
Note convertible at $5.85 per share [Member]
Shares issued for a note conversion, conversion price		5.85
Note convertible at $5.03 per share [Member]
Shares issued for a note conversion, conversion price		5.03
Note convertible at $5.14 per share [Member]
Shares issued for a note conversion, conversion price		5.14
Note convertible at $5.00 per share [Member]
Shares issued for a note conversion, conversion price		5
Note convertible at $5.26 per share [Member]
Shares issued for a note conversion, conversion price		5.26
Note convertible at $5.26 per share [Member]
Shares issued for a note conversion, conversion price		5.26
Note convertible at $5.95 per share [Member]
Shares issued for a note conversion, conversion price		5.95
Note convertible at $5.05 per share [Member]
Shares issued for a note conversion, conversion price		5.05
Note convertible at $2.90 per share [Member]
Shares issued for a note conversion, conversion price	$ 2.90
Note convertible at $2.96 per share [Member]
Shares issued for a note conversion, conversion price	2.96
Note convertible at $2.91 per share [Member]
Shares issued for a note conversion, conversion price	2.91
Note convertible at $2.77 per share [Member]
Shares issued for a note conversion, conversion price	2.77
Note convertible at $2.25 per share [Member]
Shares issued for a note conversion, conversion price	2.25
Note convertible at $2.00 per share [Member]
Shares issued for a note conversion, conversion price	2
Note convertible at $2.27283 per share [Member]
Shares issued for a note conversion, conversion price	2.27283
Note convertible at $2.0179 per share [Member]
Shares issued for a note conversion, conversion price	2.0179
Note convertible at $2.00 per share [Member]
Shares issued for a note conversion, conversion price	2
Note convertible at $1.92417 per share [Member]
Shares issued for a note conversion, conversion price	1.92417
Note convertible at $1.8578 per share [Member]
Shares issued for a note conversion, conversion price	1.8578
Shares issued at $20.63 per share [Member]
Share issue price per share		20.63
Shares issued at $18.75 per share [Member]
Share issue price per share		18.75
Shares issued at $19.50 per share [Member]
Share issue price per share		$ 19.50
Number of shareholders to whom shares issued | item		16
Shares issued at $11.25 per share [Member]
Share issue price per share		$ 11.25
Shares issued at $18.75 per share [Member]
Share issue price per share		18.75
Shares issued at $19.50 per share [Member]
Share issue price per share		$ 19.50
Number of shareholders to whom shares issued | item		16
Shares issued at $19.50 per share [Member]
Share issue price per share		$ 19.50
Number of shareholders to whom shares issued | item		16
Shares issued at $19.50 per share [Member]
Share issue price per share		$ 19.50
Number of shareholders to whom shares issued | item		16
Shares issued at $9.75 per share [Member]
Share issue price per share	$ 9.75
Number of shareholders to whom shares issued | item	16
Shares issued at $9.75 per share [Member]
Share issue price per share	$ 9.75
Number of shareholders to whom shares issued | item	16
Shares issued at $9.75 per share [Member]
Share issue price per share	$ 9.75
Number of shareholders to whom shares issued | item	16
Option exercisable at $1.25 per share [Member]
Shares issued for option exercise, exercise price		$ 1.25
Option exercisable at $5.25 per share [Member]
Shares issued for option exercise, exercise price		5.25
Option exercisable at $5.25 per share [Member]
Shares issued for option exercise, exercise price		5.25
Warrant exercisable at $15.00 per share [Member]
Shares issued for warrant exercise, exercise price		15
Warrant exercisable at $12.75 per share [Member]
Shares issued for warrant exercise, exercise price		12.75
Warrant exercisable at $.75 per share [Member]
Shares issued for warrant exercise, exercise price		0.75
Warrant exercisable at $13.50 per share [Member]
Shares issued for warrant exercise, exercise price		13.50
Warrant exercisable at $7.50 per share [Member]
Shares issued for warrant exercise, exercise price		7.50
Warrant exercisable at $5.63 per share [Member]
Shares issued for warrant exercise, exercise price		5.63
Warrant exercisable at $12.75 per share [Member]
Shares issued for warrant exercise, exercise price		12.75
Warrant exercisable at $11.25 per share [Member]
Shares issued for warrant exercise, exercise price		11.25
Warrant exercisable at $13.50 per share [Member]
Shares issued for warrant exercise, exercise price		13.50
Warrant exercisable at $9.75 per share [Member]
Shares issued for warrant exercise, exercise price		9.75
Warrant exercisable at $5.63 per share [Member]
Shares issued for warrant exercise, exercise price		$ 5.63

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flow from operating activities:
Net loss	$ (1,411,122)	$ (3,352,949)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	39,021	25,829
Vested stock options and warrants	302,981	369,636
Equity instruments issued for management and consulting	(3,333)	$ 111,917
Amortization of debt discount	219,097
Penalty on debt provision	10,031
Loss on Sales of Equipment	$ 13,102
(Gain) loss on valuation of equity-linked instruments		$ (11,469)
Changes in assets and liabilities:
Accounts receivable	$ 41,694	(52,395)
Inventories	109,699	(238,488)
Prepaid expense and other assets	(12,576)	(88,936)
Accounts payable	279,669	563,224
Accrued expenses	193,781	790,158
Deferred Revenue	3,375	(64,000)
Net cash used in operating activities:	$ (214,581)	(1,947,473)
Cash flow from investing activities:
Purchase of fixed assets		(72,377)
Purchase of intangibles	$ (7,700)	(14,782)
Net cash used in investing activities	(7,700)	(87,159)
Cash flow from financing activities:
Proceeds from long-term and convertible debt	$ 250,000	125,000
Principal payments on debt		(300,000)
Issuance of preferred stock		2,055,000
Issuance of common stock		92,831
Net cash provided by (used in) financing activities	$ 250,000	1,972,831
Net increase (decrease) in cash	27,719	(61,801)
Cash at beginning of period	16,384	101,953
Cash at end of period	$ 44,103	40,151
Non cash transactions:
Common stock issued for accrued interest/bonus		$ 694,500
Common stock issued to satisfy debt	$ 483,478

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. As of June 30, 2015, the registrant had 3,312,863 .01 The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and has a stockholders' deficit. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. In July 2015, we filed a registration statement with the SEC in connection with a proposed public offering of a Series B Convertible Preferred Stock and Series A Warrants (the “Units”). We continue to pursue this public offering, with the intention of listing our common stock and the Units on NASDAQ. Since inception to June 30, 2015, the Company raised approximately $ 9,168,000 2,055,000 5,685,000 Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-10, Development Stage Entities Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 during the year 2014. In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made. Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company's sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company's accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $ 500 1,417 1,250 7,793 Research and Development 58,285 120,947 131,285 249,636 Revenue Recognition The Company recognizes revenue in accordance with the SEC's Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605-Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company's standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company's standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer's right of return is limited only to the Company's standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management's assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: June 30, December 31, 2015 2014 Finished goods $ 46,845 $ 88,362 Raw materials 200,654 237,556 Work-In-Process 10,169 41,449 Total $ 257,668 $ 367,367 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 7 Leasehold improvements 5 Manufacturing tooling 3 7 Demo Equipment 3 The Company's investment in Fixed Assets consists of the following: June 30, 2015 December 31, 2014 Computers and office equipment $ 122,889 $ 123,708 Leasehold improvements 23,874 23,874 Manufacturing tooling 97,288 97,288 Demo Equipment 13,706 30,576 Total 257,757 275,446 Less: Accumulated depreciation 110,514 78,967 Total Fixed Assets, Net $ 147,243 $ 196,479 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $ 1,444 2,888 0 Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2011 remain open to examination by federal and state tax authorities. Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. Subsequent Events As described in Note 3 below, on July 24, 2015, the Company amended its Certificate of Incorporation, pursuant to which the authorized common stock was increased to 100,000,000 20,000,000 On February 4, 2014, the Company raised $ 2,055,000 20,550 0.01 100 Series A Preferred Shares In connection with the Company's proposed offering of 1,666,667 units (the “Units”), each consisting of one share of the Company's common stock, one share of the Company's Series B Convertible Preferred Stock and four of the Company's Series A Warrants, the holders of a majority of the Series A Preferred Shares have, as of July 20, 2015, agreed to exchange all of the outstanding Series A Preferred Shares for units with the same terms as the Units (the “Exchange Units”) such that for every dollar of stated value of Series A Preferred Shares tendered the holders will receive an equivalent value of Exchange Units based on the public offering price of the Units in this offering (the “Unit Exchange”). Accordingly, assuming the public offering price for the Units is $9.00 per Unit, then all of the Series A Preferred Shares will be exchanged into 228,334 Exchange Units. The warrants that were issued in connection with the issuance of the Series A Preferred Shares will remain outstanding; however, the warrant amounts will be reduced so that the warrants will be exercisable into an aggregate of 84,770 shares of the Company's common stock. The Unit Exchange is subject to and will be consummated currently with the consummation of the Company's offering of Units. Each holder of Series A Preferred Shares that has agreed to the terms of the Unit Exchange has entered into the Exchange Agreement with the Company. Upon effectiveness of the Unit Exchange, the Series A Preferred Shares will be cancelled and resume the status of authorized but unissued shares of preferred stock. From July through September 2014, the Company entered into a series of securities purchase agreements pursuant to which the Company issued approximately $ 1.8 2014 Convertible Notes 1.6 275,000 2015 Convertible Notes Convertible Notes 927,663 933,073 140 1.4 167,031 Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company's financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10-K filed with the SEC on April 30, 2015. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

DEVELOPMENT STAGE OPERATIONS

DEVELOPMENT STAGE OPERATIONS	6 Months Ended
	Jun. 30, 2015
DEVELOPMENT STAGE OPERATIONS [Abstract]
DEVELOPMENT STAGE OPERATIONS	NOTE 2 – DEVELOPMENT STAGE OPERATIONS The Company was formed April 23, 2002. Since inception to July 30, 2015, 3,312,863 125.25

STOCKHOLDERS' DEFICIT, STOCK OP

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS	6 Months Ended
	Jun. 30, 2015
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS [Abstract]
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS	NOTE 3 – STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years. On February 4, 2014, (the “Closing Date”) we raised $ 2,055,000 0.01 20,550 21,334 24.38 61,539 The Securities Purchase Agreement requires the Company to register the resale of the shares of Common Stock underlying the Preferred Shares (the “Underlying Shares”) and the Common Stock underlying the Warrants (the “Warrant Shares”). On September 9, 2014, a resale registration statement covering the Underlying Shares, the Warrant Shares and certain other securities (the “Resale Registration Statement”) was declared effective. The Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the “New Issuance Price”), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange 4.99 2,055,000 The Warrants are exercisable on any day on or after the date of issuance, have an adjusted exercise price of $9.75 per share, subject to possible further adjustment, and a term of five years from the date they are first exercisable. However, a holder will be prohibited from exercising a Warrant if, as a result of such exercise, the holder, together with its affiliates, would exceed the Beneficial Ownership Limitation as described above for the Preferred Shares. If any Warrant has not been fully exercised prior to the first anniversary of the Closing and if during such period the Company has not installed or received firm purchase orders (accepted by the Company) for at least 500 STREAMWAY ® Automated Surgical Fluid Disposal Systems, then, the number of shares of Common Stock for which such Warrant may be exercised shall be increased to 2.5 times the previous amount. In January 2015, the number of shares of Common Stock for which each Warrant may be exercised was increased according to this provision. As described in Note 1 under “Subsequent Events”, the Company and the holders of the Preferred Shares have agreed to the exchange of the Preferred Shares for certain units, with an agreed-upon reduction in the number of shares for which each Warrant may be exercised. In addition, in July, August and September 2014, the Company issued 71,257 Accounting for share-based payment The Company has adopted ASC 718- Compensation-Stock Compensation ("ASC 718"). Under ASC 718 stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after January 1, 2006 and unvested awards outstanding at January 1, 2006. Compensation costs for unvested stock options and non-vested awards that were outstanding at January 1, 2006, are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a straight-line method. We elected the modified-prospective method under which prior periods are not retroactively restated. ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future. Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. In January 2014 the Company issued 4,336 1.25 In January through March 2014, 9 warrant holders exercised warrants through a cashless exercise for a total of 15,442 In January and February 2014 the Company issued warrants to purchase 21,538 24.38 In February 2014 the Company issued a warrant to purchase 1,482 20.25 On March 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6 19.50 970 In March 2014, the Company issued 4,444 11.25 3,333 In June 2014, the Company issued 3,725 On June 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6 19.50 1,561 On June 30, 2014, the Company issued a warrant to purchase 5,431 12.38 11 4,831 12.38 In July 2014, the Company issued warrants to purchase 28,986 12.38 11 In August 2014, the Company issued warrants to purchase 61,539 24.38 In August and September 2014, the Company issued warrants to purchase 37,440 12.38 11 On September 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6 19.50 1,561 In November 2014, the Company issued 13,700 0.01 On December 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6 19.50 1,559 For grants of stock options and warrants in 2014 the Company used a 1.44 2.75 0 59 66 5 10 3.2006 13.9195 In January 2015, the Company issued a dividend adjustment to the Purchasers of the Preferred Shares as described above. Certain previous dividends paid were calculated with an exercise price of $ 19.50 9.75 3,122 On March 31, 2015, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6 9.75 3,121 On June 30, 2015, the Company issued dividends to Purchases of the Preferred Shares as described above. The dividends are at an annual rate of 6% 9.75 3,121 For grants of stock options and warrants in 2015 the Company used a 1.63 2.35 0 59 66 5 10 0.2750 5.5695 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Average Average Number of Exercise Number of Exercise Shares Price Shares Price Outstanding at December 31, 2013 385,733 $ 6.75 461,920 $ 10.50 Issued 75,683 8.12 161,375 3.81 Expired (7,879 ) 23.58 (81,851 ) 13.54 Exercised (4,936 ) 1.76 (40,722 ) 8.38 Outstanding at December 31, 2014 448,601 $ 7.51 500,722 $ 7.95 Issued 66,926 3.14 126,310 13.49 Expired (7,136 ) 13.55 (1,567) 14.04 Exercised - - - - Outstanding at June 30, 2015 508,391 $ 6.96 625,465 $ 9.06 At June 30, 2015, 501,723 6.31 6.43 302,981 352,762 72,354 9 The following summarizes the status of options and warrants outstanding at June 30, 2015: Range of Prices Shares Weighted Remaining Life Options $ 0.75 7,333 6.02 $ 3.10 59,681 10.00 $ 3.45 7,245 9.76 $ 4.875 134 7.70 $ 5.25 2,031 7.19 $ 5.625 192,000 7.71 $ 5.925 23,206 7.72 $ 6.00 123,998 7.13 $ 6.50 3,845 9.51 $ 6.60 5,332 6.57 $ 8.25 3,636 9.26 $ 9.9375 3,019 8.04 $ 10.50 3,238 8.04 $ 11.25 13,666 7.60 $ 12.75 3,401 8.29 $ 13.875 2,160 8.76 $ 15.00 3,334 8.72 $ 17.25 40,261 8.69 $ 18.75 3,334 8.65 $ 20.25 4,940 8.51 $ 21.75 1,336 8.28 $ 23.85 1,260 8.26 508,391 Warrants $ 0.75 400 0.44 $ 6.00 102,857 2.71 $ 9.00 2,666 2.58 $ 9.75 155,545 4.10 $ 11.25 203,801 2.52 $ 12.375 71,257 4.11 $ 12.38 5,557 4.36 $ 13.50 4,444 2.97 $ 14.85 23,612 2.92 $ 20.25 1,481 3.63 $ 24.375 53,845 3.60 625,465 Stock options and warrants expire on various dates from December 2015 to June 2025. The shareholders approved an increase in authorized shares to 1,066,067 2,666,667 The shareholders approved an increase in authorized shares to 4,000,000 The shareholders approved an amendment of the Company's 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 666,667 266,667 An increase from 4,000,000 10,666,667 1,333,334 On July 24, 2015, an amendment to the Certificate of Incorporation became effective, pursuant to which the authorized common stock was to 100,000,000 20,000,000 Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of June 30, 2015 by year of grant: Stock Options: Year Shares Price 2011 11,666 $ 0.75 2012 126,029 5.25 6.00 2013 238,088 4.875 23.85 2014 65,681 6.50 18.75 2015 66,926 3.10 3.45 Total 508,391 $ .75 25.613 Warrants: Year Shares Price 2010 400 0.75 2011 - - 2012 69,801 11.25 2013 267,579 6.00 14.85 2014 161,375 12.375 24.375 2015 126,310 $ 9.75 Total 625,465 $ 0.75 24.375

SHORT-TERM NOTES PAYABLE

SHORT-TERM NOTES PAYABLE	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Short-term Debt [Text Block]	NOTE 4 – SHORT-TERM NOTES PAYABLE From July through September 2014, we entered into a series of securities purchase agreements pursuant to which we issued approximately $ 1.8 million original principal amount (subsequently reduced to approximately $ 1.6 1,475,000 122,196 5,431 100,000 275,000 250,000 Under a provision in the existing agreements, upon effectiveness of a resale registration statement covering certain shares, on September 9, 2014, the principal amount of the notes was reduced by 11 1,603,260 11 71,257 As of June 30, 2015, $ 927,663 933,073 As described in Note 1 under “Subsequent Events”, in connection with the Company's proposed offering of Units, the holders of the Convertible Notes have agreed to not exercise their right to convert the Convertible Notes into shares of the Company's common stock, in exchange for the Company's agreement to redeem all of the outstanding Convertible Notes promptly following the consummation of the Company's offering of Units at a redemption price equal to 140 1.4 167,031

LOSS PER SHARE

LOSS PER SHARE	6 Months Ended
	Jun. 30, 2015
LOSS PER SHARE [Abstract]
LOSS PER SHARE	NOTE 5 - LOSS PER SHARE The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator: Net loss available in basic and diluted calculation $ (1,185,327 ) $ (1,735,954 ) $ (1,411,122 ) $ (3,352,949 ) Denominator: Weighted average common shares outstanding-basic 3,263,356 2,968,279 3,182,706 2,958,965 Effect of diluted stock options and warrants (1) - - - - Weighted average common shares outstanding-basic 3,263,356 2,968,279 3,182,706 2,958,965 Loss per common share-basic and diluted $ (0.36 ) $ (0.58 ) $ (0.44 ) $ (1.13 ) (1) The number of shares underlying options and warrants outstanding as of June 30, 2015 and June 30, 2014 are 1,133,856 and 847,848 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2015
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 6 – INCOME TAXES The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. There is no income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a 100 During September 2013, the Company experienced an "ownership change" as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company's net operating losses (NOLs). The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company's value immediately before the ownership change. At June 30, 2015, the Company had approximately $ 19.9 beginning in 2022 12.6 2022 through 2034 8.1 1.0 The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. The components of deferred income taxes at June 30, 2015 and December 31, 2014 are as follows: June 30, December 31, 2015 2014 Deferred Tax Asset: Net Operating Loss $ 7,919,000 $ 7,919,000 Other 1,150,000 1,150,000 Total Deferred Tax Asset 9,069,000 9,069,000 Less Valuation Allowance 9,069,000 9,069,000 Net Deferred Income Taxes $ — $ —

RENT OBLIGATION

RENT OBLIGATION	6 Months Ended
	Jun. 30, 2015
RENT OBLIGATION [Abstract]
RENT OBLIGATION	NOTE 7 – RENT OBLIGATION The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five 15,823 34,256 June 30, 2015 and was $ 15,447 and $ 33,056 for the three and six months ended June 30, 2014 respectively. The Company's rent obligation for the next five years is as follows: 2015 $ 18,500 2016 $ 38,000 2017 $ 39,000 2018 $ 3,600 2019 $ -

LIABILITY FOR EQUITY-LINKED FIN

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2015
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS [Abstract]
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS	NOTE 8 – LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS The Company adopted ASC 815- Derivatives and Hedging (“ASC 815”) on January 1, 2009. ASC 815 mandates a two-step process for evaluating whether an equity-linked financial instrument or embedded feature is indexed to the entity's own stock. It was effective for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, which was the Company's first quarter of 2009. Many of the warrants issued by the Company contain a strike price adjustment feature, which upon adoption of ASC 815, changed the classification (from equity to liability) and the related accounting for warrants with a $ 479,910 486,564 6,654 479,910 The January 1, 2009 valuation was computed using the Black-Scholes valuation model based upon a 2.5 63 34.50 26.25 1.37 were valued, using the Black-Scholes valuation model on their date of grant and an entry was made to reduce paid-in capital and increase the liability for equity-linked financial instruments. These warrants were also re-valued at the end of each quarter based upon their expected life, the stock price, the exercise price, assumed dividend rate, expected volatility and risk free interest rate. A significant reduction in the liability was realized in 2010 primarily due to a reduction from $ 37.50 16.50 In 2014, all warrants expired and the liability was reduced to zero . The inputs to the Black-Scholes model during 2009 through 2014 were as follows: Stock price $ 3.75 37.50 Exercise price $ .75 25.613 Expected life 2.0 6.5 years Expected volatility 59% Assumed dividend rate - % Risk-free interest rate .13 2.97 The original valuations, annual gain /( loss) and end of year valuations are shown below: Initial Value Annual Gain (Loss) Value at 12/31/09 2010 Gain (Loss) Value at 12/31/10 2011 Gain (Loss) Value at 12/31/2011 2012 Gain (Loss) Value at 12/31/2012 2013 Gain (Loss) Value at 12/31/2013 2014 Gain (Loss) Value at 12/31/2014 January 1, 2009 adoption $ $ (390,368 $ 870,278 $ $ $ (88,290 $ 89,796 $ (21,856 $ 111,652 $ 100,053 $ 11,599 $ 11,599 $ - Warrants issued in quarter ended 169,854 149,007 147,403 1,604 (4,689 6,293 6,293 - - - - - Warrants issued in quarter ended 39,743 40,419 62 (1,562 1,624 910 714 714 - - - Warrants issued in quarter ended 12,698 617 12,081 12,053 28 (724) 752 415 337 337 - - - Subtotal 702,205 1,071,847 Warrants issued in quarter ended 25,553 25,014 539 (5,570 6,109 3,701 2,408 2,408 - - - Warrants issued in quarter ended 31,332 30,740 592 (6,122 6,714 6,083 631 631 - - - Warrants issued in quarter ended 31,506 20,891 10,615 (44,160 54,775 1,338 53,437 53,437 - - - Total $ 790,596 $ (369,642 $ $ $ 14,946 $ (151,117 $ 166,063 $ (3,116 $ 169,179 $ 157,580 $ 11,599 $ 11,599 $ -

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2015
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. Rick Koenigsberger, a director, is a holder of membership units in SOK Partners. Convertible Note Issuances to Dr. Samuel Herschkowitz and SOK Partners, LLC On September 11, 2013, both the Herschkowitz Note and the SOK Note (each as defined below in this Note 9) were converted in full by the holders thereof at $ 0.014 314,484 299,509 680,444 648,050 The remaining disclosure of this Note 9 provides historical information regarding the Herschkowitz Note, the SOK Note and certain other convertible note issuances. On March 28, 2012, the Company, entered into a Convertible Note Purchase Agreement, dated as of March 28, 2012 (the “SOK Purchase Agreement”) with SOK Partners, LLC (“SOK Partners”), and an investment partnership. Josh Kornberg, who is the Company's Chief Executive Officer and interim Chairman of the Board, and Dr. Samuel Herschkowitz are affiliates of the manager of SOK Partners and Ricardo Koenigsberger, a director, is a holder of membership units of SOK Partners. Pursuant to the SOK Purchase Agreement, the Company issued a 20.0 600,000 24 On March 28, 2012, the Company received an advance of $ 84,657 60,000 300,000 4.88 61,539 300,000 61,539 300,000 600,000 357,282 As long as any amount payable under the SOK Note remained outstanding, SOK Partners or its designee were entitled to appoint a new member to the Company's Board of Directors, to be appointed upon request. Ricardo Koenigsberger was appointed to the Board by SOK Partners on June 25, 2012. On March 28, 2012, the Company signed an Amended and Restated Note Purchase Agreement, dated as of December 20, 2011, with Dr. Samuel Herschkowitz (as amended, the “Herschkowitz Purchase Agreement”). Pursuant to the Herschkowitz Purchase Agreement, the Company issued a 20.0 240,000 20,623 As long as any amount payable under the Herschkowitz Note remained outstanding, Dr. Herschkowitz or his designee was entitled to appoint a special advisor to the Company's Board of Directors, to be appointed as a member of the Board upon request. Pursuant to this authority, Josh Kornberg was appointed to the Board on March 9, 2012. In addition, pursuant to this authority, Mr. Koenigsberger was appointed to the Board on June 25, 2012. Pursuant to a letter dated April 20, 2012, Dr. Herschkowitz advised the Company of the occurrence of numerous events of default under the terms of the Herschkowitz Note and the Herschkowitz Note Purchase Agreement. As a result of such events of default, Dr. Herschkowitz asserted significant rights as a secured creditor of the Company, including his rights as a secured creditor with a security interest in substantially all assets of the Company. Without a settlement relating to the defaults and other matters, Dr. Herschkowitz could have taken action to levy upon the Company's assets, including patents and other intellectual property. In addition, the Company and Atlantic Partners Alliance LLC (“APA”) were parties to a letter agreement dated March 14, 2012, providing APA and its affiliates (including Dr. Herschkowitz and SOK) with rights to avoid dilution relating to additional issuances of equity securities by the Company through July 14, 2012, evidencing the parties' intent that APA would be provided with significant protection against dilution. This protection was in recognition of APA's investments in the Company involving a high degree of risk and the Company's contemplated need for restructuring its indebtedness, which were anticipated to result, and have resulted, in significant dilution. The parties acknowledged that Dr. Herschkowitz and SOK would not have made their historical cash investments in the Company to the same degree had the dilution protection not been provided, and the investments by these parties have enabled the Company to avoid insolvency. Since the respective dates of the Herschkowitz Note Purchase Agreement and the SOK Note Purchase Agreement, the Company has issued in excess of 213,334 Effective August 15, 2012, the Company entered into a letter agreement with Dr. Herschkowitz, APA and SOK (the “Forbearance Agreement”). Under the Forbearance Agreement, among other things, (i) Dr. Herschkowitz agreed to forbear from asserting his rights as a secured creditor to substantially all of the Company's assets, resulting from the Company's defaults; (ii) the Company issued an aggregate 353,334 1.05 4.88 In the Forbearance Agreement, Dr. Herschkowitz agreed to forbear from exercising any of his rights arising under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement with respect to the existing defaults against the Company, subject to the limitations set forth in the letter agreement and without releasing or waiving any future breach of the letter agreement. He further agreed to forbear from exercising any rights with respect to events of default, security interests in the collateral and other similar remedies against the Company or his interests under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement until the occurrence of an event of default under the Herschkowitz Note: (a) that does not constitute an existing default; and (b) occurs and accrues after the effective date of the letter agreement. Dr. Herschkowitz and the Company acknowledged that 100,000 20 24 20 Under the Forbearance Agreement, the Herschkowitz Note and the SOK Note were amended as follows: (i) the due dates of the notes were extended to December 31, 2012 from the previous due dates of June 20, 2012 and August 28, 2012, respectively; (ii) Dr. Herschkowitz will release his security agreement after payment of all currently outstanding promissory notes to parties other than SOK; and (iii) the Herschkowitz Note was amended to add certain events of default relating to judgments against the Company or other creditors taking action with respect to the collateral. In consideration of the extension additional milestone fees were revised as described below. Pursuant to a Forbearance and Settlement Agreement with these parties dated August 15, 2012, as subsequently amended, the due date of these notes were extended to August 31, 2013 APA and its affiliates agreed to terminate the letter agreement regarding dilution dated March 14, 2012. In consideration of the various provisions of the letter agreement and in recognition of the understanding of the parties regarding dilution and the agreements of APA and its affiliates to forbear and to extend the due dates of the notes, the Company (i) issued 176,667 176,667 1.05 4.88 In the event that the Company consummated the following series of transactions on or prior to June 30, 2013: (i) a merger or similar transaction with a public shell company, (ii) raising between $ 2 4 listing the Company's shares on NASDAQ pursuant to an underwritten offering of the Company's securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have been required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round; and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses. In connection with the extension of the due date for the Herschkowitz Note and the SOK Note on March 6, 2013, the milestone fees were revised. The following fees were payable to Dr. Herschkowitz in the event that the Company consummates the following series of transactions on or prior to December 31, 2013: (i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000; and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million. On January 6, 2014 a side-letter to the forbearance agreement was signed between Dr. Herschkowitz and the Company. Skyline agreed that the private offering for its Series A Convertible Preferred Stock, plus any future offering of any class of its preferred stock, shall be considered a NASDAQ underwriting for purposes of Section 8(e) of the Forbearance Agreement. As such Dr. Herschkowitz received $200,000 or 3% of the gross proceeds of any such offering per the terms of Section 8(e) of the Forbearance Agreement. In addition, any listing of the Company's shares on the New York Stock Exchange shall qualify as a NASDAQ underwriting under the Forbearance Agreement. For the avoidance of doubt, the payment in the aggregate for all offerings qualifying as a NASDAQ underwriting shall under no circumstances be less than $200,000 or greater than $1,000,000. Section 8(e) of the Forbearance Agreement will apply to any transactions consummated by Skyline on or before June 30, 2014. As a result of the transactions under the Forbearance Agreement and other investments, Dr. Herschkowitz, SOK and their affiliates currently own shares of common stock and securities representing beneficial ownership of approximately 48% of the Company's outstanding common stock, giving such parties significant control over election of the Board of Directors and other matters. On November 6, 2012, the Company issued and sold convertible promissory notes in the total principal amount of $ 156,243 20,833 20 155,000 13,889 7.50 In December 2013 the Company received an additional $ 300,000 February 28, 2014 10 10 250,000 20,000 20 305,589.04 In connection with the sale of the Preferred Shares on February 4, 2014 as described in Note 3, Josh Kornberg, our CEO, was one of the Purchasers. Mr. Kornberg purchased 19,231 25,000 52 On July 23, 2014, the Company entered into the a securities purchase agreement pursuant to which the Company agreed to issue and sell convertible notes and warrants to SOK, under the terms described in Note 4 of this Report. SOK's note (the “SOK Note”) had an original principal amount of $ 122,196 5,431 100,000 8.7 108,696 4,831 140

Retirement Savings Plan

Retirement Savings Plan	6 Months Ended
	Jun. 30, 2015
Retirement Savings Plan [Abstract]
Retirement Savings Plan	Note 10 – Retirement Savings Plan We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2015 and 2014, we matched 100 4 6,652 14,713 8,171 12,304

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 11 – Commitments and Contingencies On July 17, 2014, Skyline Medical Inc. (the “Company”) and a stockholder entered into a settlement agreement and release (the “Settlement Agreement”) with Marshall Ryan (“Ryan”) and a company related to Ryan (together, the “Plaintiffs”). The settlement relates to a previously disclosed lawsuit by the Plaintiffs initiated in March 2014. Ryan is an engineer who previously worked with the Company on design of certain of the Company's products. The lawsuit alleged among other things, breach of a 2008 consulting agreement, a 2006 manufacturing agreement and a 2006 supply agreement among the Plaintiffs and the Company, various claims of fraud and negligent misrepresentation, and breach of the duty of good faith and fair dealing. Under the Settlement Agreement, the parties have agreed that the lawsuit will be dismissed. The Company has agreed to pay Ryan an aggregate of $ 500,000 200,000 Payment of the outstanding balance under the Settlement Agreement will be accelerated if the Company raises $2 million or more of gross dollars in a single funding round or raises aggregate funding of $4 million of gross dollars on or before April 10, 2015 The Settlement Agreement also contains mutual releases covering claims other than a breach of the Settlement Agreement. In the Settlement Agreement, Ryan fully, unconditionally and irrevocably affirms and ratifies the Company's rights to Ryan's prior patent assignments, and disclaims any right, title or interest in the Company's Streamway product including any claims to royalties both past and future. In addition, the parties confirmed that the patents related to the Streamway product belong exclusively to Skyline and remain in full force and effect. On April 27, 2015, the Company entered into a Third Extension of Settlement Agreement (the “Third Extension”) with Ryan and the Plaintiffs. Under the Third Extension the parties have agreed that in consideration for this Memorandum of Understanding Skyline will pay Ryan $ 50,000 18 that if Skyline obtains gross funding, as measured from all its funding and revenue beginning on April 1, 2015 , in the amounts specified below, payment shall accelerate as follows: if Skyline obtains gross funding of at least $2,000,000 or more but less than $4,000,000, it shall immediately pay $250,000 to Ryan toward the current balance; if Skyline obtain gross funding of at least $4,000,000 or more, it shall immediately pay any portion of the current balance, third extension payment and interest not already paid. Additionally, incremental payments to be deducted from the current balance will be made in the following amounts: Skyline will pay $15,000 on or before May 29, 2015 . Darryl C. Demaray, Brady P. Farrell, Christopher S. Howell and Ronald W. Walters v. Skyline Medical Inc. four

Supplemental Cash Flow Data

Supplemental Cash Flow Data	6 Months Ended
	Jun. 30, 2015
Supplemental Cash Flow Data [Abstract]
Supplemental Cash Flow Data	Note 12 – Supplemental Cash Flow Data Cash payments for interest were $ 441 10,161 3,468 21,606

SUMMARY OF SIGNIFICANT ACCOUN20

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Recent Accounting Developments	Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-10, Development Stage Entities Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 during the year 2014. In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations.
Valuation of Intangible Assets	Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made.
Accounting Policies and Estimates	Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Presentation Of Taxes Collected From Customers	Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company's sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company's accounting policy is to exclude the taxes collected and remitted from revenues and expenses.
Shipping and Handling	Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.
Advertising	Advertising Advertising costs are expensed as incurred. Advertising expenses were $ 500 1,417 1,250 7,793
Research and Development	Research and Development 58,285 120,947 131,285 249,636
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with the SEC's Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605-Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company's standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company's standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer's right of return is limited only to the Company's standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur.
Receivables	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management's assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements.
Inventories	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: June 30, December 31, 2015 2014 Finished goods $ 46,845 $ 88,362 Raw materials 200,654 237,556 Work-In-Process 10,169 41,449 Total $ 257,668 $ 367,367
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 7 Leasehold improvements 5 Manufacturing tooling 3 7 Demo Equipment 3 The Company's investment in Fixed Assets consists of the following: June 30, 2015 December 31, 2014 Computers and office equipment $ 122,889 $ 123,708 Leasehold improvements 23,874 23,874 Manufacturing tooling 97,288 97,288 Demo Equipment 13,706 30,576 Total 257,757 275,446 Less: Accumulated depreciation 110,514 78,967 Total Fixed Assets, Net $ 147,243 $ 196,479 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
Intangible Assets	Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $ 1,444 2,888 0
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2011 remain open to examination by federal and state tax authorities.
Patents and Intellectual Property	Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023.
Subsequent Events	Subsequent Events As described in Note 3 below, on July 24, 2015, the Company amended its Certificate of Incorporation, pursuant to which the authorized common stock was increased to 100,000,000 20,000,000 On February 4, 2014, the Company raised $ 2,055,000 20,550 0.01 100 Series A Preferred Shares In connection with the Company's proposed offering of 1,666,667 units (the “Units”), each consisting of one share of the Company's common stock, one share of the Company's Series B Convertible Preferred Stock and four of the Company's Series A Warrants, the holders of a majority of the Series A Preferred Shares have, as of July 20, 2015, agreed to exchange all of the outstanding Series A Preferred Shares for units with the same terms as the Units (the “Exchange Units”) such that for every dollar of stated value of Series A Preferred Shares tendered the holders will receive an equivalent value of Exchange Units based on the public offering price of the Units in this offering (the “Unit Exchange”). Accordingly, assuming the public offering price for the Units is $9.00 per Unit, then all of the Series A Preferred Shares will be exchanged into 228,334 Exchange Units. The warrants that were issued in connection with the issuance of the Series A Preferred Shares will remain outstanding; however, the warrant amounts will be reduced so that the warrants will be exercisable into an aggregate of 84,770 shares of the Company's common stock. The Unit Exchange is subject to and will be consummated currently with the consummation of the Company's offering of Units. Each holder of Series A Preferred Shares that has agreed to the terms of the Unit Exchange has entered into the Exchange Agreement with the Company. Upon effectiveness of the Unit Exchange, the Series A Preferred Shares will be cancelled and resume the status of authorized but unissued shares of preferred stock. From July through September 2014, the Company entered into a series of securities purchase agreements pursuant to which the Company issued approximately $ 1.8 2014 Convertible Notes 1.6 275,000 2015 Convertible Notes Convertible Notes 927,663 933,073 140 1.4 167,031

SUMMARY OF SIGNIFICANT ACCOUN21

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Schedule of inventory	June 30, December 31, 2015 2014 Finished goods $ 46,845 $ 88,362 Raw materials 200,654 237,556 Work-In-Process 10,169 41,449 Total $ 257,668 $ 367,367
Schedule of property, plant and equipment	Years Computers and office equipment 3 7 Leasehold improvements 5 Manufacturing tooling 3 7 Demo Equipment 3
Schedule of investment in fixed Assets	June 30, 2015 December 31, 2014 Computers and office equipment $ 122,889 $ 123,708 Leasehold improvements 23,874 23,874 Manufacturing tooling 97,288 97,288 Demo Equipment 13,706 30,576 Total 257,757 275,446 Less: Accumulated depreciation 110,514 78,967 Total Fixed Assets, Net $ 147,243 $ 196,479

STOCKHOLDERS' DEFICIT, STOCK 22

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2015
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS [Abstract]
Summary of Transactions for Stock Options and Warrants	Stock Options Warrants Average Average Number of Exercise Number of Exercise Shares Price Shares Price Outstanding at December 31, 2013 385,733 $ 6.75 461,920 $ 10.50 Issued 75,683 8.12 161,375 3.81 Expired (7,879 ) 23.58 (81,851 ) 13.54 Exercised (4,936 ) 1.76 (40,722 ) 8.38 Outstanding at December 31, 2014 448,601 $ 7.51 500,722 $ 7.95 Issued 66,926 3.14 126,310 13.49 Expired (7,136 ) 13.55 (1,567) 14.04 Exercised - - - - Outstanding at June 30, 2015 508,391 $ 6.96 625,465 $ 9.06
Summary of Status of Options and Warrants Outstanding	Range of Prices Shares Weighted Remaining Life Options $ 0.75 7,333 6.02 $ 3.10 59,681 10.00 $ 3.45 7,245 9.76 $ 4.875 134 7.70 $ 5.25 2,031 7.19 $ 5.625 192,000 7.71 $ 5.925 23,206 7.72 $ 6.00 123,998 7.13 $ 6.50 3,845 9.51 $ 6.60 5,332 6.57 $ 8.25 3,636 9.26 $ 9.9375 3,019 8.04 $ 10.50 3,238 8.04 $ 11.25 13,666 7.60 $ 12.75 3,401 8.29 $ 13.875 2,160 8.76 $ 15.00 3,334 8.72 $ 17.25 40,261 8.69 $ 18.75 3,334 8.65 $ 20.25 4,940 8.51 $ 21.75 1,336 8.28 $ 23.85 1,260 8.26 508,391 Warrants $ 0.75 400 0.44 $ 6.00 102,857 2.71 $ 9.00 2,666 2.58 $ 9.75 155,545 4.10 $ 11.25 203,801 2.52 $ 12.375 71,257 4.11 $ 12.38 5,557 4.36 $ 13.50 4,444 2.97 $ 14.85 23,612 2.92 $ 20.25 1,481 3.63 $ 24.375 53,845 3.60 625,465
Schedule of Listing of Stock Options and Warrants	Stock Options: Year Shares Price 2011 11,666 $ 0.75 2012 126,029 5.25 6.00 2013 238,088 4.875 23.85 2014 65,681 6.50 18.75 2015 66,926 3.10 3.45 Total 508,391 $ .75 25.613 Warrants: Year Shares Price 2010 400 0.75 2011 - - 2012 69,801 11.25 2013 267,579 6.00 14.85 2014 161,375 12.375 24.375 2015 126,310 $ 9.75 Total 625,465 $ 0.75 24.375

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2015
LOSS PER SHARE [Abstract]
Schedule of Shares Used in Basic and Diluted Loss Per Common Share Computations	Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator: Net loss available in basic and diluted calculation $ (1,185,327 ) $ (1,735,954 ) $ (1,411,122 ) $ (3,352,949 ) Denominator: Weighted average common shares outstanding-basic 3,263,356 2,968,279 3,182,706 2,958,965 Effect of diluted stock options and warrants (1) - - - - Weighted average common shares outstanding-basic 3,263,356 2,968,279 3,182,706 2,958,965 Loss per common share-basic and diluted $ (0.36 ) $ (0.58 ) $ (0.44 ) $ (1.13 ) (1) The number of shares underlying options and warrants outstanding as of June 30, 2015 and June 30, 2014 are 1,133,856 and 847,848 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

INCOME TAXES (Tables)

INCOME TAXES (Tables)	6 Months Ended
	Jun. 30, 2015
INCOME TAXES [Abstract]
Schedule of Components of Deferred Income Taxes	June 30, December 31, 2015 2014 Deferred Tax Asset: Net Operating Loss $ 7,919,000 $ 7,919,000 Other 1,150,000 1,150,000 Total Deferred Tax Asset 9,069,000 9,069,000 Less Valuation Allowance 9,069,000 9,069,000 Net Deferred Income Taxes $ — $ —

RENT OBLIGATION (Tables)

RENT OBLIGATION (Tables)	6 Months Ended
	Jun. 30, 2015
RENT OBLIGATION [Abstract]
Schedule of Rent Obligation	2015 $ 18,500 2016 $ 38,000 2017 $ 39,000 2018 $ 3,600 2019 $ -

LIABILITY FOR EQUITY-LINKED F26

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Jun. 30, 2015
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS [Abstract]
Schedule of Inputs to Black-Scholes Model	Stock price $ 3.75 37.50 Exercise price $ .75 25.613 Expected life 2.0 6.5 years Expected volatility 59% Assumed dividend rate - % Risk-free interest rate .13 2.97
Schedule of Original Valuations, Annual Gain/(Loss) and End of Year Valuations	Initial Value Annual Gain (Loss) Value at 12/31/09 2010 Gain (Loss) Value at 12/31/10 2011 Gain (Loss) Value at 12/31/2011 2012 Gain (Loss) Value at 12/31/2012 2013 Gain (Loss) Value at 12/31/2013 2014 Gain (Loss) Value at 12/31/2014 January 1, 2009 adoption $ $ (390,368 $ 870,278 $ $ $ (88,290 $ 89,796 $ (21,856 $ 111,652 $ 100,053 $ 11,599 $ 11,599 $ - Warrants issued in quarter ended 169,854 149,007 147,403 1,604 (4,689 6,293 6,293 - - - - - Warrants issued in quarter ended 39,743 40,419 62 (1,562 1,624 910 714 714 - - - Warrants issued in quarter ended 12,698 617 12,081 12,053 28 (724) 752 415 337 337 - - - Subtotal 702,205 1,071,847 Warrants issued in quarter ended 25,553 25,014 539 (5,570 6,109 3,701 2,408 2,408 - - - Warrants issued in quarter ended 31,332 30,740 592 (6,122 6,714 6,083 631 631 - - - Warrants issued in quarter ended 31,506 20,891 10,615 (44,160 54,775 1,338 53,437 53,437 - - - Total $ 790,596 $ (369,642 $ $ $ 14,946 $ (151,117 $ 166,063 $ (3,116 $ 169,179 $ 157,580 $ 11,599 $ 11,599 $ -

SUMMARY OF SIGNIFICANT ACCOUN27

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - Relationship to Entity [Domain] - USD ($)	Jun. 30, 2015	Jul. 23, 2014	May. 31, 2015	Nov. 30, 2014	Feb. 28, 2014	Apr. 30, 2013	Apr. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Jun. 30, 2015	Jul. 24, 2015	Sep. 30, 2014	Feb. 04, 2014	Sep. 10, 2013	Apr. 15, 2013	Jan. 15, 2013	Sep. 07, 2011	Jun. 22, 2010
Summary Of Significant Accounting Policy [Line Items]
Common Stock, Shares, Outstanding	3,312,863							3,312,863		3,312,863		3,092,766	3,312,863
Common Stock, Par or Stated Value Per Share	$ 0.01			$ 0.01				$ 0.01		$ 0.01		$ 0.01	$ 0.01
Stockholders' Equity, Period Increase (Decrease)													$ 9,168,000
Stock Issued During Period, Value, New Issues										$ 2,055,000		$ 2,055,001
Debt Instrument, Increase (Decrease) for Period, Net										5,685,000
Amortization of Intangible Assets								$ 1,444	$ 0	2,888	$ 0
Advertising Expense								500	1,250	1,417	7,793
Research and Development Expense								$ 58,285	$ 131,285	$ 120,947	$ 249,636
Common stock, shares authorized	100,000,000							100,000,000		100,000,000		100,000,000	100,000,000					666,667	4,000,000	2,666,667	1,066,067
Preferred stock, shares authorized	20,000,000							20,000,000		20,000,000		20,000,000	20,000,000
Stock Issued During Period, Shares, New Issues				13,700		13,889
Preferred Stock, Par or Stated Value Per Share	$ 0.01							$ 0.01		$ 0.01		$ 0.01	$ 0.01
Proposed offering, Description					In connection with the Company's proposed offering of 1,666,667 units (the “Units”), each consisting of one share of the Company's common stock, one share of the Company's Series B Convertible Preferred Stock and four of the Company's Series A Warrants, the holders of a majority of the Series A Preferred Shares have, as of July 20, 2015, agreed to exchange all of the outstanding Series A Preferred Shares for units with the same terms as the Units (the “Exchange Units”) such that for every dollar of stated value of Series A Preferred Shares tendered the holders will receive an equivalent value of Exchange Units based on the public offering price of the Units in this offering (the “Unit Exchange”). Accordingly, assuming the public offering price for the Units is $9.00 per Unit, then all of the Series A Preferred Shares will be exchanged into 228,334 Exchange Units. The warrants that were issued in connection with the issuance of the Series A Preferred Shares will remain outstanding; however, the warrant amounts will be reduced so that the warrants will be exercisable into an aggregate of 84,770 shares of the Company's common stock. The Unit Exchange is subject to and will be consummated currently with the consummation of the Company's offering of Units. Each holder of Series A Preferred Shares that has agreed to the terms of the Unit Exchange has entered into the Exchange Agreement with the Company. Upon effectiveness of the Unit Exchange, the Series A Preferred Shares will be cancelled and resume the status of authorized but unissued shares of preferred stock.
Original principal amount	$ 933,073							$ 933,073		$ 933,073			$ 933,073
Amount of aggregate principal amount converted into shares of the Company's common stock	927,663
Redemption price as percentage of the principal amount, plus accrued and unpaid interest		140.00%								140.00%
Estimated total redemption price	1,400,000							1,400,000		$ 1,400,000			1,400,000
Estimated total redemption price that will be paid to affiliates	$ 167,031							$ 167,031		167,031			$ 167,031
Magna Equities II, LLC [Member]
Summary Of Significant Accounting Policy [Line Items]
Original principal amount			$ 275,000
2014 Convertible Notes [Member]
Summary Of Significant Accounting Policy [Line Items]
Original principal amount			275,000												$ 1,800,000
Reduced principal amount															1,600,000
Amount of aggregate principal amount converted into shares of the Company's common stock			$ 250,000
SOK Partners, LLC, [Member] | 2014 Convertible Notes [Member]
Summary Of Significant Accounting Policy [Line Items]
Original principal amount															$ 122,196
Minimum [Member]
Summary Of Significant Accounting Policy [Line Items]
Common stock, shares authorized																	4,000,000
Maximum [Member]
Summary Of Significant Accounting Policy [Line Items]
Common stock, shares authorized																	10,666,667
Samuel Herschkowitz [Member]
Summary Of Significant Accounting Policy [Line Items]
Stock Issued During Period, Shares, New Issues							100,000
Series A Convertible Preferred Stock [Member]
Summary Of Significant Accounting Policy [Line Items]
Stock Issued During Period, Value, New Issues					$ 2,055,000					$ 2,055,000
Stock Issued During Period, Shares, New Issues					20,550
Preferred Stock, Par or Stated Value Per Share																$ 0.01
Stated value per share																$ 100
Subsequent Event [Member]
Summary Of Significant Accounting Policy [Line Items]
Common stock, shares authorized														100,000,000
Preferred stock, shares authorized														20,000,000

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Inventory) (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Finished goods	$ 46,845	$ 88,362
Raw materials	200,654	237,556
Work-In-Process	10,169	41,449
Total	$ 257,668	$ 367,367

SUMMARY OF SIGNIFICANT ACCOUN29

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property, Plant and Equipment) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Estimated useful of assets [Line items]
Total	$ 257,757	$ 275,446
Less: Accumulated depreciation	110,514	78,967
Total Fixed Assets, Net	147,243	196,479
Computers and office equipment [Member]
Estimated useful of assets [Line items]
Total	$ 122,889	123,708
Computers and office equipment [Member] | Minimum [Member]
Estimated useful of assets [Line items]
Property, Plant and Equipment, Useful Life	3 years
Computers and office equipment [Member] | Maximum [Member]
Estimated useful of assets [Line items]
Property, Plant and Equipment, Useful Life	7 years
Leasehold Improvements [Member]
Estimated useful of assets [Line items]
Property, Plant and Equipment, Useful Life	5 years
Total	$ 23,874	23,874
Manufacturing Tooling [Member]
Estimated useful of assets [Line items]
Total	$ 97,288	97,288
Manufacturing Tooling [Member] | Minimum [Member]
Estimated useful of assets [Line items]
Property, Plant and Equipment, Useful Life	3 years
Manufacturing Tooling [Member] | Maximum [Member]
Estimated useful of assets [Line items]
Property, Plant and Equipment, Useful Life	7 years
Demo Equipment [Member]
Estimated useful of assets [Line items]
Property, Plant and Equipment, Useful Life	3 years
Total	$ 13,706	$ 30,576

DEVELOPMENT STAGE OPERATIONS (D

DEVELOPMENT STAGE OPERATIONS (Details) - $ / shares	Jul. 30, 2015	Dec. 31, 2009
Development stage operation [Line Items]
Common Stock, Shares, Issued	3,312,863
Equity Issuance Per Share Amount	$ 125.25	$ 26.25

STOCKHOLDERS' DEFICIT, STOCK 31

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Narrative) (Details) - Short-term Debt, Type [Domain] - Related Party [Domain] - USD ($)	Jun. 30, 2015	Sep. 09, 2014	Mar. 31, 2015	Jan. 31, 2015	Nov. 30, 2014	Sep. 30, 2014	Jul. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Feb. 28, 2014	Jan. 31, 2014	Apr. 30, 2013	Mar. 31, 2012	Sep. 30, 2014	Sep. 30, 2014	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2009	Jul. 24, 2015	Aug. 31, 2014	Aug. 04, 2014	Jul. 23, 2014	Feb. 04, 2014	Sep. 10, 2013	Apr. 15, 2013	Jan. 15, 2013	Sep. 07, 2011	Jun. 22, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Life																				2 years 6 months
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate																			0.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum																			59.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum																			66.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Volatility Description																	The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach.
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																				1.37%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	501,723																501,723
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 6.31																$ 6.31
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term 1																	6 years 5 months 5 days
Share-based Compensation Expense																	$ 302,981	$ 352,762
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Stock Options	$ 72,354																$ 72,354
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1																	9 months
Common stock, shares authorized	100,000,000																100,000,000		100,000,000								666,667	4,000,000	2,666,667	1,066,067
Debt Instrument, Face Amount	$ 933,073																$ 933,073
Preferred Stock, Par or Stated Value Per Share	$ 0.01																$ 0.01		$ 0.01
Common stock, par value (in dollars per share)	$ 0.01				$ 0.01												$ 0.01		$ 0.01
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 12.38	$ 11.25	$ 24.38						$ 11.25		$ 12.38
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						37,440	28,986	4,831		21,538				37,440	37,440			4,831				61,539	61,539	5,431
Stock Issued During Period, Value, New Issues																	$ 2,055,000		$ 2,055,001
Stock Issued During Period, Shares, New Issues					13,700							13,889
Preferred Stock Conversion Price, Per Share				$ 19.50		$ 19.50		$ 19.50											$ 19.50
Convertible Preferred Stock, Terms of Conversion																	The Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the “New Issuance Price”), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange
Beneficial Ownership Limitation, Percentage																	4.99%
Preferred Shareholders, Receivable, Upon Any Liquidation, Description																	2,055,000
Cashless Exercise Of Common Stock Warrants Total									3,333							15,442
Stock Issued During Period, Shares, Conversion of Convertible Securities	3,121		3,121	3,122		1,561		1,561	970										1,559
Conversion Of Stock Price Per Share	$ 9.75		$ 9.75	$ 9.75					$ 19.50
Preferred Stock, Dividend Rate, Percentage	6.00%		6.00%			6.00%		6.00%	6.00%										6.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period								3,725	4,444
Stock Issued During Period, Shares, Other													20,623
Preferred stock, shares authorized	20,000,000																20,000,000		20,000,000
SOK Partners, LLC, [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 12.38										$ 12.38
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		71,257						5,431										5,431
Percentage Of Reduction To Warrant Agreement		11.00%
Dr.Samuel Herschowitz [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 20.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										1,482
CEO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price											$ 1.25
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period											4,336
Two Lenders [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 12.38
Four Lenders [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 12.38								$ 12.38	$ 12.38
Purchasers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																						$ 24.38
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized																					100,000,000
Preferred stock, shares authorized																					20,000,000
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price																	$ 13.49		$ 3.81
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 24.38
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										21,334
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price																			$ 8.38
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period																			40,722
Stock Issued During Period, Shares, Other															71,257
Warrant [Member] | Two Lenders [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage Of Reduction To Warrant Agreement							11.00%
Warrant [Member] | Four Lenders [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage Of Reduction To Warrant Agreement														11.00%
Series A Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred Stock, Par or Stated Value Per Share																									$ 0.01
Stock Issued During Period, Value, New Issues										$ 2,055,000
Stock Issued During Period, Shares, New Issues										20,550
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized																										1,333,334
Shares Grants Increase For Threshold																											266,667
Stock Options and Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate																	0.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum																	59.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum																	66.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Life																	2 years
Common stock, shares authorized																										4,000,000
Minimum [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price																	$ 0.75
Minimum [Member] | Stock Options and Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Life																	5 years		5 years
Issued - Average Exercise Price																	$ 0.2750		$ 3.2006
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																	1.63%		1.44%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Life																	6 years 6 months
Common stock, shares authorized																										10,666,667
Maximum [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price																	$ 24.375
Maximum [Member] | Stock Options and Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Life																	10 years		10 years
Issued - Average Exercise Price																	$ 5.5695		$ 13.9195
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																	2.35%		2.75%

STOCKHOLDERS' DEFICIT, STOCK 32

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Summary of Transactions for Stock Options and Warrants) (Details) - $ / shares	1 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercised - Number of shares	(3,725)	(4,444)
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of shares			448,601	385,733
Issued - Number of shares			66,926	75,683
Expired - Number of shares			(7,136)	(7,879)
Exercised - Number of shares				(4,936)
Outstanding Number of shares			508,391	448,601
Outstanding - Average Exercise Price			$ 7.51	$ 6.75
Issued - Average Exercise Price			3.14	8.12
Expired - Average Exercise Price			$ 13.55	23.58
Exercised - Average Exercise Price				1.76
Outstanding - Average Exercise Price			$ 6.96	$ 7.51
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of shares			500,722	461,920
Issued - Number of shares			126,310	161,375
Expired - Number of shares			(1,567)	(81,851)
Exercised - Number of shares				(40,722)
Outstanding Number of shares			625,465	500,722
Outstanding - Average Exercise Price			$ 7.95	$ 10.50
Issued - Average Exercise Price			13.49	3.81
Expired - Average Exercise Price			$ 14.04	13.54
Exercised - Average Exercise Price				8.38
Outstanding - Average Exercise Price			$ 9.06	$ 7.95

STOCKHOLDERS' DEFICIT, STOCK 33

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Summary of Status of Options and Warrants Outstanding) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2009	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Life		2 years 6 months
Stock Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 0.75
Shares	7,333
Weighted Average Remaining Life	6 years 7 days
Stock Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 3.10
Shares	59,681
Weighted Average Remaining Life	10 years
Stock Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 3.45
Shares	7,245
Weighted Average Remaining Life	9 years 9 months 4 days
Stock Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 4.875
Shares	134
Weighted Average Remaining Life	7 years 8 months 12 days
Stock Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 5.25
Shares	2,031
Weighted Average Remaining Life	7 years 2 months 8 days
Stock Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 5.625
Shares	192,000
Weighted Average Remaining Life	7 years 8 months 16 days
Stock Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 5.925
Shares	23,206
Weighted Average Remaining Life	7 years 8 months 19 days
Stock Options Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 6
Shares	123,998
Weighted Average Remaining Life	7 years 1 month 17 days
Stock Options Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 6.50
Shares	3,845
Weighted Average Remaining Life	9 years 6 months 4 days
Stock Options Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 6.60
Shares	5,332
Weighted Average Remaining Life	6 years 6 months 25 days
Stock Options Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 8.25
Shares	3,636
Weighted Average Remaining Life	9 years 3 months 4 days
Stock Options Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 9.9375
Shares	3,019
Weighted Average Remaining Life	8 years 14 days
Stock Options Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 10.50
Shares	3,238
Weighted Average Remaining Life	8 years 14 days
Stock Options Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 11.25
Shares	13,666
Weighted Average Remaining Life	7 years 7 months 6 days
Stock Options Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 12.75
Shares	3,401
Weighted Average Remaining Life	8 years 3 months 14 days
Stock Options Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 13.875
Shares	2,160
Weighted Average Remaining Life	8 years 9 months 4 days
Stock Options Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 15
Shares	3,334
Weighted Average Remaining Life	8 years 8 months 19 days
Stock Options Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 17.25
Shares	40,261
Weighted Average Remaining Life	8 years 8 months 8 days
Stock Options Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 18.75
Shares	3,334
Weighted Average Remaining Life	8 years 7 months 24 days
Stock Options Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 20.25
Shares	4,940
Weighted Average Remaining Life	8 years 6 months 4 days
Stock Options Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 21.75
Shares	1,336
Weighted Average Remaining Life	8 years 3 months 11 days
Stock Options Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 23.85
Shares	1,260
Weighted Average Remaining Life	8 years 3 months 4 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 6.96		$ 7.51	$ 6.75
Shares	508,391		448,601	385,733
Warrant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 0.75
Shares	400
Weighted Average Remaining Life	5 months 8 days
Warrant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 6
Shares	102,857
Weighted Average Remaining Life	2 years 8 months 16 days
Warrant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 9
Shares	2,666
Weighted Average Remaining Life	2 years 6 months 29 days
Warrant Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 9.75
Shares	155,545
Weighted Average Remaining Life	4 years 1 month 6 days
Warrant Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 11.25
Shares	203,801
Weighted Average Remaining Life	2 years 6 months 7 days
Warrant Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 12.375
Shares	71,257
Weighted Average Remaining Life	4 years 1 month 10 days
Warrant Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 12.38
Shares	5,557
Weighted Average Remaining Life	4 years 4 months 10 days
Warrant Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 13.50
Shares	4,444
Weighted Average Remaining Life	2 years 11 months 19 days
Warrant Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 14.85
Shares	23,612
Weighted Average Remaining Life	2 years 11 months 1 day
Warrant Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 20.25
Shares	1,481
Weighted Average Remaining Life	3 years 7 months 17 days
Warrant Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 24.375
Shares	53,845
Weighted Average Remaining Life	3 years 7 months 6 days
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Prices	$ 9.06		$ 7.95	$ 10.50
Shares	625,465		500,722	461,920

STOCKHOLDERS' DEFICIT, STOCK 34

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Schedule of Listing of Stock Options and Warrants) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Warrants 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	400
Issued - Average Exercise Price	$ 0.75
Warrants 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares
Issued - Average Exercise Price
Warrants 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	69,801
Issued - Average Exercise Price	$ 11.25
Warrants 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	267,579
Warrants 2013 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 6
Warrants 2013 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 14.85
Warrants 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	161,375
Warrants 2014 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 12.375
Warrants 2014 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 24.375
Warrants 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	126,310
Warrants 2015 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 9.75
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	625,465	500,722	461,920
Issued - Average Exercise Price	$ 13.49	$ 3.81
Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	0.75
Warrant [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 24.375
Stock Options 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	11,666
Issued - Average Exercise Price	$ 0.75
Stock Options 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	126,029
Stock Options 2012 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 5.25
Stock Options 2012 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 6
Stock Options 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	238,088
Stock Options 2013 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 4.875
Stock Options 2013 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 23.85
Stock Options 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	65,681
Stock Options 2014 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 6.50
Stock Options 2014 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 18.75
Stock Options 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	66,926
Stock Options 2015 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 3.10
Stock Options 2015 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 3.45
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	508,391	448,601	385,733
Issued - Average Exercise Price	$ 3.14	$ 8.12
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	0.75
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued - Average Exercise Price	$ 25.613

SHORT-TERM NOTES PAYABLE (Detai

SHORT-TERM NOTES PAYABLE (Details) - Related Party [Domain] - USD ($)	Jun. 30, 2015	Sep. 09, 2014	Jul. 23, 2014	May. 31, 2015	Sep. 30, 2014	Jun. 30, 2015	Aug. 31, 2014	Aug. 04, 2014	Jul. 31, 2014	Jun. 30, 2014	Feb. 28, 2014
Short-term Debt [Line Items]
Original principal amount	$ 933,073					$ 933,073
Amount of aggregate principal amount converted into shares of the Company's common stock	927,663
Shares of common stock exercisable for warrants			5,431		37,440		61,539	61,539	28,986	4,831	21,538
Aggregate purchase price			$ 100,000
Redemption price as percentage of the principal amount, plus accrued and unpaid interest			140.00%			140.00%
Estimated total redemption price	1,400,000					$ 1,400,000
Estimated total redemption price that will be paid to affiliates	$ 167,031					$ 167,031
SOK Partners, LLC, [Member]
Short-term Debt [Line Items]
Shares of common stock exercisable for warrants		71,257								5,431
Aggregate purchase price					$ 100,000
Percentage of reduction to principal amount of the notes		11.00%
Notes Payable, Current		$ 1,603,260
Percentage Of Reduction To Warrant Agreement		11.00%
2014 Convertible Notes [Member]
Short-term Debt [Line Items]
Original principal amount				$ 275,000	1,800,000
Reduced principal amount					1,600,000
Amount of aggregate principal amount converted into shares of the Company's common stock				$ 250,000
Aggregate purchase price					1,475,000
2014 Convertible Notes [Member] | SOK Partners, LLC, [Member]
Short-term Debt [Line Items]
Original principal amount					$ 122,196
Shares of common stock exercisable for warrants					5,431

LOSS PER SHARE (Schedule of Sha

LOSS PER SHARE (Schedule of Shares Used in Basic and Diluted Loss Per Common Share Computations) (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Numerator:
Net loss available in basic and diluted calculation		$ (1,185,327)	$ (1,735,954)	$ (1,411,122)	$ (3,352,949)
Denominator:
Weighted average common shares outstanding-basic		3,263,356	2,968,279	3,182,706	2,958,965
Effect of diluted stock options and warrants	[1]
Weighted average common shares outstanding-basic		3,263,356	2,968,279	3,182,706	2,958,965
Loss per common share-basic and diluted		$ (0.36)	$ (0.58)	$ (0.44)	$ (1.13)
[1]	The number of shares underlying options and warrants outstanding as of June 30, 2015 and June 30, 2014 are 1,133,856 and 847,848 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

LOSS PER SHARE (Narrative) (Det

LOSS PER SHARE (Narrative) (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
LOSS PER SHARE [Abstract]
Options and Warrants Outstanding	$ 1,133,856	$ 847,848

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Tax Credit Carryforward [Line Items]
Valuation Allowance Percentage	100.00%
Operating Loss Carryforwards, Expiration Period	December 312,022
Domestic Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Operating Loss Carryforwards	$ 19.9
Operating Loss Carryforwards, Valuation Allowance		$ 8.1
Operating Loss Carryforwards, Expiration Period	beginning in 2022
State and Local Jurisdiction [Member]
Tax Credit Carryforward [Line Items]
Operating Loss Carryforwards		12.6
Operating Loss Carryforwards, Valuation Allowance		$ 1
Operating Loss Carryforwards, Expiration Period		2022 through 2034

INCOME TAXES (Schedule of Compo

INCOME TAXES (Schedule of Components of Deferred Income Taxes) (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Deferred Tax Asset:
Net Operating Loss	$ 7,919,000	$ 7,919,000
Other	1,150,000	1,150,000
Total Deferred Tax Asset	9,069,000	9,069,000
Less Valuation Allowance	$ 9,069,000	$ 9,069,000
Net Deferred Income Taxes

RENT OBLIGATION (Narrative) (De

RENT OBLIGATION (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
RENT OBLIGATION [Abstract]
Operating Leases, Rent Expense	$ 15,823	$ 15,447	$ 34,256	$ 33,056
Lease Expiration Date			Jan. 31, 2018
Lease Period Extended			5 years

RENT OBLIGATION (Schedule of Re

RENT OBLIGATION (Schedule of Rent Obligation) (Details)	Jun. 30, 2015USD ($)
RENT OBLIGATION [Abstract]
2,015	$ 18,500
2,016	38,000
2,017	39,000
2,018	$ 3,600
2,019

LIABILITY FOR EQUITY-LINKED F42

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Narrative) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2010	Dec. 31, 2009	Jul. 30, 2015	Dec. 31, 2014	Jan. 02, 2009
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Warrants Not Settleable In Cash, Fair Value Disclosure						$ 479,910
Weighted Average Remaining Life			2 years 6 months
Additional Paid in Capital						486,564
Retained Earnings (Accumulated Deficit)						6,654
Total Current Liabilities	$ 6,889,678				$ 6,203,321	$ 479,910
Expected volatility	59.00%		63.00%
Exercise price			$ 34.50
Share Price			$ 26.25	$ 125.25
Risk-free interest rate			1.37%
Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Weighted Average Remaining Life	2 years
Reduction In Stock Price		$ 37.50
Exercise price	$ 0.75
Share Price	$ 3.75
Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Weighted Average Remaining Life	6 years 6 months
Reduction In Stock Price		$ 16.50
Exercise price	$ 25.613
Share Price	$ 37.50

LIABILITY FOR EQUITY-LINKED F43

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Schedule of Inputs to Black-Scholes Model) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2009	Jul. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price			$ 26.25	$ 125.25
Exercise price			$ 34.50
Expected life			2 years 6 months
Expected volatility	59.00%		63.00%
Assumed dividend rate		0.00%
Risk-free interest rate - Minimum	0.13%
Risk-free interest rate - Maximum	2.97%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price	$ 3.75
Exercise price	$ 0.75
Expected life	2 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price	$ 37.50
Exercise price	$ 25.613
Expected life	6 years 6 months

LIABILITY FOR EQUITY-LINKED F44

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Schedule of Original Valuations, Annual Gain/(Loss) and End of Year Valuations) (Details) - USD ($)	3 Months Ended						9 Months Ended	12 Months Ended
	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2009	Sep. 30, 2009	Jun. 30, 2009	Sep. 30, 2010	Dec. 31, 2009	Dec. 31, 2008
Class of Warrant or Right [Line Items]
Initial Value	$ 31,506	$ 31,332	$ 25,553	$ 12,698	$ 39,743	$ 169,854		$ 702,205	$ 479,910
Annual Gain (Loss)				617	(738)	20,847	$ (369,642)		(390,368)
Total							790,596
Value At 2009 [Member]
Class of Warrant or Right [Line Items]
Initial Value				12,081	40,481	149,007		$ 1,071,847	870,278
Total							1,071,847
Value At 2010 [Member]
Class of Warrant or Right [Line Items]
Initial Value	10,615	592	539	28	62	1,604			1,506
Total							14,946
Gain Loss 2010 [Member]
Class of Warrant or Right [Line Items]
Annual Gain (Loss)	20,891	30,740	25,014	12,053	40,419	147,403			868,772
Total							1,145,292
Value At 2011 [Member]
Class of Warrant or Right [Line Items]
Initial Value	54,775	6,714	6,109	752	1,624	6,293			89,796
Total							166,063
Gain Loss 2011 [Member]
Class of Warrant or Right [Line Items]
Annual Gain (Loss)	(44,160)	(6,122)	(5,570)	(724)	(1,562)	$ (4,689)			(88,290)
Total							(151,117)
Value At 2012 [Member]
Class of Warrant or Right [Line Items]
Initial Value	53,437	631	2,408	337	714				111,652
Total							169,179
Gain Loss 2012 [Member]
Class of Warrant or Right [Line Items]
Annual Gain (Loss)	$ 1,338	$ 6,083	$ 3,701	$ 415	$ 910	$ 6,293			(21,856)
Total							(3,116)
Value At 2013 [Member]
Class of Warrant or Right [Line Items]
Initial Value									11,599
Total							11,599
Gain Loss 2013 [Member]
Class of Warrant or Right [Line Items]
Annual Gain (Loss)	$ 53,437	$ 631	$ 2,408	$ 337	$ 714				$ 100,053
Total							$ 157,580
Value at 2014 [Member]
Class of Warrant or Right [Line Items]
Initial Value
Gain Loss 2014 [Member]
Class of Warrant or Right [Line Items]
Annual Gain (Loss)									$ 11,599
Total							$ 11,599

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)

Jul. 23, 2014

Sep. 11, 2013

Nov. 30, 2014

Feb. 28, 2014

Jan. 31, 2014

Dec. 31, 2013

Apr. 30, 2013

Nov. 30, 2012

Aug. 31, 2012

May. 31, 2012

Apr. 30, 2012

Mar. 31, 2012

Jun. 30, 2015

Dec. 31, 2014

Sep. 30, 2014

Sep. 09, 2014

Aug. 31, 2014

Aug. 04, 2014

Jul. 31, 2014

Jun. 30, 2014

Feb. 04, 2014

Dec. 31, 2012

Aug. 15, 2012

Mar. 28, 2012

Mar. 14, 2012

Related party transaction [Line Items]

Convertible note (as a percentage)

20.00%

20.00%

20.00%

Principal amount

$ 156,243

$ 600,000

$ 240,000

Effective interest rate (as a percent)

24.00%

Advance under note

300,000

Cash advance net Of interest

$ 60,000

Conversion price (in dollars per share)

$ 0.014

$ 7.50

$ 4.88

Conversion of units

$ 600,000

Other shares issued (in shares)

20,623

Shares issued, three (in shares)

20,833

Proceeds from related party debt

$ 155,000

Convertible note due date

Aug. 31, 2013

Description of transaction

(i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000; and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million. On January 6, 2014 a side-letter to the forbearance agreement was signed between Dr. Herschkowitz and the Company. Skyline agreed that the private offering for its Series A Convertible Preferred Stock, plus any future offering of any class of its preferred stock, shall be considered a NASDAQ underwriting for purposes of Section 8(e) of the Forbearance Agreement. As such Dr. Herschkowitz received $200,000 or 3% of the gross proceeds of any such offering per the terms of Section 8(e) of the Forbearance Agreement. In addition, any listing of the Company's shares on the New York Stock Exchange shall qualify as a NASDAQ underwriting under the Forbearance Agreement. For the avoidance of doubt, the payment in the aggregate for all offerings qualifying as a NASDAQ underwriting shall under no circumstances be less than $200,000 or greater than $1,000,000. Section 8(e) of the Forbearance Agreement will apply to any transactions consummated by Skyline on or before June 30, 2014.

Shares issued

13,700

13,889

Compensation payment pursuant to merger

listing the Company's shares on NASDAQ pursuant to an underwritten offering of the Company's securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have been required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round; and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses.

Value of new shares issued

$ 2,055,000

$ 2,055,001

Number of securities called by warrants or rights

5,431

21,538

37,440

61,539

61,539

28,986

4,831

Original principal amount

$ 933,073

Aggregate purchase price

$ 100,000

Redemption price, percentage

140.00%

140.00%

Preferred stock [Member]

Related party transaction [Line Items]

Value of new shares issued

$ 206

Common stock [Member]

Related party transaction [Line Items]

Value of new shares issued

Non-convertible grid note [Member]

Related party transaction [Line Items]

Effective interest rate (as a percent)

10.00%

Minimum [Member]

Related party transaction [Line Items]

Proceeds from offering of securities

$ 2,000,000

Maximum [Member]

Related party transaction [Line Items]

Proceeds from offering of securities

$ 4,000,000

First advance [Member]

Related party transaction [Line Items]

Advance under note

$ 300,000

Second advance [Member]

Related party transaction [Line Items]

Advance under note

$ 84,657

Samuel Herschkowitz [Member]

Related party transaction [Line Items]

Shares issued, two (in shares)

353,334

Shares issued

100,000

Accrued interest (as a percent)

20.00%

Periodic payment

$ 314,484

Number of shares converted

299,509

Samuel Herschkowitz [Member] | Non-convertible grid note [Member]

Related party transaction [Line Items]

Gross proceeds received in advance (as a percent)

10.00%

Samuel Herschkowitz [Member] | Minimum [Member]

Related party transaction [Line Items]

Conversion price (in dollars per share)

$ 1.05

Interest rate on event of default (as a percent)

20.00%

Samuel Herschkowitz [Member] | Maximum [Member]

Related party transaction [Line Items]

Conversion price (in dollars per share)

$ 4.88

Interest rate on event of default (as a percent)

24.00%

Sok Partners [Member]

Related party transaction [Line Items]

Notes payable

$ 357,282

Advance under note

$ 300,000

Conversion of units (in shares)

61,539

61,539

Additional issue Of common stock (in shares)

213,334

Shares issued

176,667

Periodic payment

$ 680,444

Number of shares converted

648,050

Sok Partners [Member] | Non-convertible grid note [Member]

Related party transaction [Line Items]

Notes payable

$ 305,589.04

Proceeds from notes payable

$ 20,000

$ 300,000

Maturity date

Feb. 28, 2014

Amount received in three tranches

$ 250,000

Increase in interest in case of default

20.00%

Dr. Samuel Herschkowitz and SOK Partners, LLC [Member]

Related party transaction [Line Items]

Shares issued

176,667

Dr. Samuel Herschkowitz and SOK Partners, LLC [Member] | Minimum [Member]

Related party transaction [Line Items]

Equity bonus valued at common stock (in dollars per share)

$ 1.05

Dr. Samuel Herschkowitz and SOK Partners, LLC [Member] | Maximum [Member]

Related party transaction [Line Items]

Equity bonus valued at common stock (in dollars per share)

$ 4.88

SOK Partners, LLC, [Member]

Related party transaction [Line Items]

Number of securities called by warrants or rights

4,831

Original principal amount

$ 122,196

$ 108,696

Original issue discount (as a percent)

8.70%

CEO [Member]

Related party transaction [Line Items]

Number of securities called by warrants or rights

52

CEO [Member] | Preferred stock [Member]

Related party transaction [Line Items]

Shares issued

25,000

Value of new shares issued

$ 19,231

Retirement Savings Plan (Detail

Retirement Savings Plan (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Retirement Savings Plan [Abstract]
Employer matching contribution (as a percent)			100.00%
Maximum contributions per employee (as a percent)			4.00%
Employer contribution	$ 6,652	$ 8,171	$ 14,713	$ 12,304

Commitments and Contingencies (

Commitments and Contingencies (Details)	Apr. 29, 2015item	Apr. 27, 2015USD ($)	Jun. 30, 2015USD ($)
Commitments and Contingencies [Line Items]
Settlement amount		$ 50,000	$ 500,000
Litigation liability payable			$ 200,000
Interest percentage		18.00%
Settlement agreement term		that if Skyline obtains gross funding, as measured from all its funding and revenue beginning on April 1, 2015 , in the amounts specified below, payment shall accelerate as follows: if Skyline obtains gross funding of at least $2,000,000 or more but less than $4,000,000, it shall immediately pay $250,000 to Ryan toward the current balance; if Skyline obtain gross funding of at least $4,000,000 or more, it shall immediately pay any portion of the current balance, third extension payment and interest not already paid. Additionally, incremental payments to be deducted from the current balance will be made in the following amounts: Skyline will pay $15,000 on or before May 29, 2015 .	Payment of the outstanding balance under the Settlement Agreement will be accelerated if the Company raises $2 million or more of gross dollars in a single funding round or raises aggregate funding of $4 million of gross dollars on or before April 10, 2015
Darryl C. Demaray, Brady P. Farrell, Christopher S. Howell and Ronald W. Walters v. Skyline Medical Inc [Member]
Commitments and Contingencies [Line Items]
Number of plaintiffs | item	4

Supplemental Cash Flow Data (De

Supplemental Cash Flow Data (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Supplemental Cash Flow Data [Abstract]
Cash payments for interest	$ 441	$ 3,468	$ 10,161	$ 21,606